Tag Archives: Syndromes

Rasagaline and restless leg syndrome

A new study has claimed that a drug prescribed for Parkinson’s disease could also treat restless leg syndrome (RLS) without the adverse side effects of current therapies.

Rasagaline works by prolonging the effect of dopamine, a chemical that transmits signals between nerve cells in the brain.

The cause of RLS is unknown, but research suggests a dopamine imbalance. Parkinson”s is caused by a dopamine insufficiency.

“The hope is that Rasagaline, because it prolongs the effect of existing dopamine, instead of producing more, will not come with adverse side effects,” said Dr. Shyamal Mehta, a neurologist and neuroscientist at Medical College of Georgia.

“We are trying to evaluate its safety and efficacy in treating RLS at this point. When it has been used to treat Parkinson”s, it’s been well-tolerated with few side effects,” he added.

Rasagaline

Rasagaline

Current RLS therapies include a group drugs that work by activating existing dopamine receptors, prompting the brain to make more dopamine.

Mehta said the problem is that those drugs usually come with adverse effects, because dopamine increases feelings of euphoria.

“People taking those drugs often report behavioral problems like addiction, because the pleasure they get from things like shopping is multiplied,” he said.


“They can cause impulse-control problems, like gambling or hypersexuality as well. They can also cause increased sleepiness and sudden sleep attacks, which can be quite disruptive and dangerous,” he added.

Some reports also suggested decreased efficacy after extended use, as well as symptoms beginning earlier in the day.

Restless leg syndrome, which affects 10 percent of the population, is characterized by prickling or tingling in the legs and an urge to move the legs.

Symptoms are more noticeable at rest, such as during bedtime or a long car ride.

RLS can also cause depression and daytime sleepiness, and is linked to conditions including iron deficiency, renal failure, pregnancy and Parkinson”s, said Mehta.

Soy could treat Sanfilippo

A naturally occurring chemical found in soy could prove to be an effective new treatment for a fatal genetic disease that affects children, according to University of Manchester scientists.

Brian Bigger, from the University”s MPS Stem Cell Research Laboratory, found that genistein – derived from soya beans and licensed in the US as an osteoporosis drug – had a dramatic effect on mice suffering from the human childhood disease Sanfilippo.

“Sanfilippo is an untreatable mucopolysaccharide (MPS) disease affecting one in 89,000 children in the United Kingdom,” said Bigger.

“Children with Sanfilippo disease experience progressive deterioration of mental function, similar to dementia, in early childhood, with other symptoms including severe behavioural problems, hyperactivity and ultimately death in early teens,” Bigger said.

Soy

Soy

In the study mice with Sanfilippo disease were fed with high doses of genistein over a nine-month period.

Treated mice showed a significant delay in their mental decline, including a third reduction in the amount of excess sugars found in the brain as a result of the disease, and a sixth reduction in inflammation in the brain.

Importantly, the research, carried out with colleagues at St Mary”s Hospital in Manchester, also showed that the hyperactivity and other abnormal behaviour normally seen in Sanfilippo mice were fully corrected by genistein treatment.


The study was published in the journal Public Library of Science One.

Sanfilippo syndrome, or Mucopolysaccharidosis III (MPS-III) is a rare autosomal recessive lysosomal storage disease caused by a deficiency in one of the enzymes needed to break down the glycosaminoglycan heparan sulfate (which is found in the extra-cellular matrix and on cell surface glycoproteins).

Although undegraded heparan sulfate is the primary stored substrate, glycolipids such as gangliosides are also stored despite no genetic defect in the enzymes associated with their breakdown.

The condition is named for Sylvester Sanfilippo, the pediatrician who first described the disease.